Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ST-segment elevation myocardial infarction~* Undergoing primary percutaneous coronary intervention~* Aged between 20 and 80 years~Exclusion Criteria:~* Previous administration of any antagonist of the platelet adenosine diphosphate (ADP) P2Y12 receptor (clopidogrel, prasugrel or ticagrelor)~* History of stroke or transient ischemic attack~* Previous gastrointestinal bleeding within 6 months, bleeding diathesis, platelet count \< 100,000/mm3 or hemoglobin \< 10 g/dl~* Chronic oral anticoagulation treatment~* Contraindication to the antiplatelet treatment~* Severe renal insufficiency (serum creatine\>2.5 mg/dl)~* Severe hepatic dysfunction (serum liver enzyme or bilirubin\>3 times normal limit)~* Sever chronic obstructive pulmonary disease (COPD) or bradycardia~* Body weight \< 50 kg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel 60 mg (Type: EXPERIMENTAL): Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
- Ticagrelor 180 mg (Type: EXPERIMENTAL): Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose

Based on this trial design, predict the completion outcome and termination type (if applicable).